Integrating Depression Services Into DM Management
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01098253|
Recruitment Status : Completed
First Posted : April 2, 2010
Results First Posted : March 9, 2012
Last Update Posted : March 9, 2012
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes Mellitus Depression||Behavioral: Adherence Intervention||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||182 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Integrating Depression Services Into Type 2 Diabetes Mellitus Management|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||April 2011|
|Actual Study Completion Date :||April 2011|
Experimental: Adherence Intervention
Factors affecting adherence to oral hypoglycemic agents and antidepressants were addressed using a problem solving process.
Behavioral: Adherence Intervention
Factors affecting adherence are addressed using a problem solving process.
|No Intervention: Usual Care|
- Hemoglobin A1C [ Time Frame: 3 months ]HbA1c levels will be obtained in accordance with ADA guidelines (1) employing the in2it A1C Analyzer. The Analyzer offers accurate point of care HbA1c testing. Point of care testing using this device has acceptable precision and agreement in comparison with laboratory services
- Nine Item Patient Health Questionnaire (PHQ-9) [ Time Frame: 3 months ]Depressive symptoms were measured using the nine-item Patient Health Questionnaire (PHQ-9). PHQ-9 scored on a range from 0 to 27, where lower scores represent fewer depressive symptoms.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01098253
|United States, Pennsylvania|
|University of Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19104|
|Principal Investigator:||Hillary R. Bogner, MD||University of Pennsylvania|